Intravitreal bevacizumab monotherapy for type 1 prethreshold, threshold, and aggressive posterior retinopathy-27 months follow-up results from Turkey - Yetik, H; Gunay, M; Sirop, S (Graefes Arch Clin Exp Ophthalmol, 2015)